December 2022 Editor’s Choice: Exceptional PARP inhibitor responders: the good and the bad
Listen to Gynecologic Oncology
English - December 29, 2022 05:15Science Health & Fitness medicine health care science and technology health national health service medical disease cancer politics diabetes Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Burnout and gynecologic oncology — does the problem still exist?
Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology and Author of the editorial
Featuring: David O'Malley, MD, The Ohio State University
Editor’s Choice Paper: Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
Editorial: The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data